Archives

Patient Safety: Gabapentin and Trazadone: Off-label Use is Out of Control-Recorded Webinar

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this knowledge based CE Activity, a pharmacist will be able to:

·        LIST the numerous off label uses of gabapentin and trazodone.
·        DESCRIBE which of those uses are supported by actual evidence
·        INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
·        ARTICULATE ways to approach prescribers with alternative suggestions

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-044-H05-P

Session Code

23RW44-WYX48

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-044-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeannette Y. Wick, RPh, MBA, FASCP
Director OPPD
University of Connecticut School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Jeannette  Wick has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

CONTENT

POST TEST

Patient Safety: Gabapentin and Trazodone, Off-label Use is Out of Control
LEARNING OBJECTIVES
At the end of this continuing education activity, pharmacists will be able to
1. LIST the numerous off label uses of gabapentin and trazodone
2. DESCRIBE which of those uses are supported by actual evidence
3. INDICATE the potential adverse effects and medication related problems that patients who take these drugs may experience
4. ARTICULATE ways to approach prescribers with alternative suggestions

1. Which of the following is an off-label use for gabapentin?
A. Postherpetic neuralgia
B. Adjunctive therapy in partial seizures
C. Migraine prophylaxis

2. Which of the following is an off-label use for trazodone?
A. Chronic insomnia
B. Major depressive disorder
C. Pruritis

3. Which of gabapentin’s off-label uses has the strongest evidence to support it?
A. Bipolar disorder
B. Alcohol withdrawal syndrome
C. Pain syndromes

4. Which of trazodone’s off-label uses has the strongest evidence to support it?
A. Little evidence is available to support the use of trazodone in any of its purported off-label uses.
B. The best evidence supports its use in chronic insomnia, with more than 15 RCTs indicating it is effective.
C. A surprise finding has been that it is effective for behavioral issues in kids who have ADHD; it may help adults, too.

5. Which if the following links gabapentin and trazodone to a most common adverse effect?
A. Gabapentin = dose-dependent CNS and respiratory depression; trazodone = nausea/vomiting, xerostomia, dizziness, drowsiness
B. Gabapentin = dose-dependent CNS priapism and suicidal ideation; trazodone = hypersensitivity reactions and peripheral edema
C. Gabapentin = cardiac arrythmias and QT prolongation; trazodone = cumulative depressant effects when given with SSRIs

Handouts

VIDEO

Law: Identifying Imposters: Counterfeit Drugs in the Pharmacy Distribution Chain -RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this knowledge based CE Activity, a pharmacist will be able to:

  • Define the terms “counterfeit” and "spurious" drugs
  • Discuss the prevalence of counterfeiting globally and in the United States
  • List factors that contribute to drug counterfeiting
  • Discuss the Drug Supply Chain Security Act (DSCSA) and its implications for the drug supply distribution chain’s integrity
  • Identify steps that reduce the risk of suspect product being delivered to the pharmacy and to patients

Release and Expiration Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-25-062-H03-P

Session Code

25RW62-CDP71

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this knowledge-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-062-H03-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeannette Y. Wick, RPh, MBA, FASCP
Director OPPD
University of Connecticut School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Jeannette  Wick has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

CONTENT

Posttest

1. What is the difference between “counterfeit” and “spurious” drugs and adulterated drugs?

  1. Counterfeit or spurious drugs are usually contaminated but adulterated drugs are not
  2. Adulterated drugs are usually contaminated but counterfeit or spurious drugs are often not
  3. Counterfeit or spurious drugs and adulterated drugs are the same thing for all practical purposes

2. Approximately how many “online pharmacies” exist globally?

  1. 300 to 400
  2. 30,000 to 40,000
  3. 300,000 to 400,000

3. Which of the following medications is MOST LIKELY to be counterfeited and why?

  1. Erectile dysfunction medications because of the quantity restrictions imposed by drug manufacturers
  2. Any class of medication used frequently by the elderly because of the large volume sold across the country
  3. Monoclonal antibodies and designer oncology drugs because of their high cost and large eligible patient pool

4. A 22-year-old college student attends a weekend rave. Near the dance floor, there’s a large bucket of mixed pills in different colors and shapes. Friends tell him, “Just grab a few—everyone does it.” Which of the following is the MOST APPROPRIATE harm-reduction step for him to take?

  1. Nibble a very small piece of one pill first and wait an hour; if he feels okay, he can assume the pills are safe and take more
  2. Use a reputable test kit (e.g., reagent test, fentanyl test strip) and avoid taking any pills that he hasn’t checked
  3. Choose only pills that are a familiar color and logo (e.g., something he’s seen online) because these are more likely to be genuine

5. What is the difference between a 1D and a 2D barcode?

  1. A 1D barcode stores data in one direction while a 2D barcode stores data in two directions
  2. A 1D barcode is flat on the surface of the packaging, while a 2D barcode has texture
  3. A 1D barcode stores much more information than the typical 2D barcode

6. During an internal audit, a technician asks, “When we receive prescription drugs from a wholesaler, what information are we required to get and keep so we can verify where each product came from if there’s a recall or a counterfeiting investigation?” Which answer best reflects the Drug Supply Chain Security Act (DSCSA) requirements?

  1. A complete pedigree including product identifier and transaction information, history, and statements from trading partners
  2. Only the manufacturer’s lot number/expiration date and the product’s NDC
  3. An invoice showing the purchase price and quantity, the lot number/expiration date, and the package insert

7. Anna is a procurement manager for a large healthcare system. They recently found counterfeit Ozempic in their inventory. Which of the following steps is the MOST IMPORTANT to prevent this from happening again?

  1. Purchase medications from reputable sources approved by regulatory agencies
  2. Check all shipments of prescription drugs to ensure they’ve been shipped in the U.S.
  3. Check all inventory on the online BeSafeRx web site immediately when it arrives

Handouts

VIDEO

The ABCD of Off-Label Medications for Weight Management-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1.     Discuss the main principles of management of adiposity-based chronic disease (ABCD)
2.     Identify the efficacy of commonly prescribed medications that may be used off-label for weight reduction
3.     List major safety considerations for medications prescribed off-label for weight reduction

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-038-H01-P

Session Code

23RW38-CBA96

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-038-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Khanh Dang, PharmD, CDCES, FNAP
Clinical Professor
UConn School of Pharmacy
Storrs, CT

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Dang has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

The ABCD of Off-Label Medications for Weight Management
Post Test
1. When working with a patient to manage ABCD, what is the first goal?

A. prevent weight regain
B. stop further weight gain
C. achieve weight reduction

2. Which of the following is the correct order of weight reduction efficacy (highest to lowest)?

A. tirzepatide > semaglutide > phentermine
B. semaglutide > SGLT2 inhibitors > phentermine
C. metformin = semaglutide > topiramate

3. What did the SELECT RCT report about patients 45 years and older with ABCD and existing cardiovascular disease who did not have diabetes?

A. The placebo-subtracted weight reduction for weekly semaglutide 2.4 mg was 15% of baseline body weight.
B. Subcutaneous semaglutide 2.4 mg once weekly reduced major adverse cardiovascular events in ABCD.
C. Subcutaneous semaglutide 2.4 mg once weekly significantly reduced weight but did not prevent cardiovascular events.

4. What is the most common adverse reaction for GLP-1 receptor agonist-based medications?

A. nausea and other gastrointestinal adverse effects
B. hypoglycemia
C. sleep disturbance

5. With which drug class can tirzepatide interact ?

A. beta blockers
B. ACE inhibitors
C. oral hormonal contraceptives

Handouts

VIDEO

TOP 10 Cardiovascular Drugs Used Off Label!!!-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

  • Identify how an FDA approved and off label indication differ and the implications of that differential designation
  • Identify which 10 FDA approved cardiovascular drugs have the most promising off label uses for treating other cardiac or noncardiac disorders
  • Describe the mechanisms of action for the purported off label uses of these drugs
  • Identify which national guidelines or consensus statements recommend the off-label use of drugs

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-039-H01-P

Session Code

23RW39-TXJ88

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-039-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

C. Michael White, PharmD, FCCP, FCP
BOT Distinguished Professor and Chair of Pharmacy Practice
University of Connecticut School of Pharmacy
Storrs, CT              

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. White has no relationships with ineligible companies

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test “TOP 10 Cardiovascular Drugs Used Off Label!!!”

1. Which of the following drugs has been used to enhance the chances of delivering a baby in patients with Factor 5 Leiden and what is the mechanism of benefit?
a) Thiazide diuretics; reduced placental calcium that stops crystalline umbilical cord blockage
b) LMWH; preventing placental thrombosis in patients who are hypercoagulable
c) Disopyramide – decreasing the inotropic effect in hypertrophic cardiomyopathy that leads to placental detachment

2. Which of the following drugs is effective for treating anal fissures and what is the mechanism of action?
a) IV iron; iron deficiency anemia promotes fissure formation so treating it reverses fissure
b) Amiodarone; overactive potassium channels in the anus lead to apoptosis of anal mucosal cells
c) CCBs; Blood vessel dilation enhancing blood flow to targeted areas in the body

3. Which of the following drugs is properly linked to the off-label indication it is commonly used for?
a) Beta-blockers – Raynaud’s phenomenon
b) Prazosin – Nightmares in PTSD patients
c) Clonidine – Stage fright

4. Which of the following drugs is used off label for the treatment of abnormal face and body hair growth in patients and what is the mechanism of action?
a) Spironolactone – blocking the effects of testosterone in several ways
b) Beta-blockers – blocking epinephrine induced follicular stimulation
c) Clonidine – central outflow of norepinephrine causes abnormal hair growth

5. Sally Sue has had atrial fibrillation for several months. Her cardiologist has prescribed several therapies that have been ineffective, and one that is on the drug shortage list and hard to find. Which of the following might the cardiologist use off-label according to the AHA/ACC Guideline?

a) Calcium channel blockers
b) Prazocin
c) Amiodarone

Handouts

VIDEO

Antipsychotic Utilization in a Pediatric Population-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Describe current practice guidelines regarding the use of antipsychotic medications in a pediatric population.
2.  Outline adverse effects associated with the use of antipsychotic medication in a pediatric population.
3.  Discuss when to initiate an antipsychotic medication in a pediatric patient.

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-043-H01-P

Session Code

23RW43-XYW84

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-043-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Megan J. Ehret PharmD, MS, BCPP
Professor, Co-Director of Mental Health Program
University of Maryland School of Pharmacy
Baltimore, MD

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Ehret is a consultant with Saladex Biomedical

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Post Test

Post Test

Antipsychotic Utilization in a Pediatric Population

Megan Ehret, PharmD

 
1. Which medication is a first-line treatment option for a 14-year-old patient with newly diagnosed schizophrenia?
a. Divalproex Sodium
b. Haloperidol
C. Risperidone

2. Which medication is a first-line treatment option for a 16-year-old patient with bipolar disorder, most recent episode depressed?
A. Aripiprazole
B. Divalproex Sodium
C. Lurasidone

3. Which medication can cause the most substantial weight gain?
A. Cariprazine
B. Lumateperone
C. Olanzapine

4. Which rating scale should be used to screen patients for tardive dyskinesia?

A. Extrapyramidal Symptom Rating Scale
B. Barnes Akathisia Rating Scale
C. Abnormal Involuntary Movement Scale

5. In which disease state would it be appropriate to initiate an antipsychotic medication in a pediatric patient?
A. Autism
B. Conduct Disorder
C. Intellectual Disability

Handouts

VIDEO

Immunization: It is Now Time to Make it Unclear: Reconciling Differences between Public Health Vaccine Recommendations and FDA Product Labeling-RECORDED WEBINAR

About this Course

This course is a recorded (home study version) of the CE Finale Encore Webinars.

 

Learning Objectives

Upon completion of this application based CE Activity, a pharmacist will be able to:

1. Compare and contrast the roles & activities of the Center for Biologics Evaluations and Research (CBER), US Food & Drug Administration (FDA), Centers for Disease Control & Prevention (CDC), and the Advisory Committee on Immunization Practices (ACIP) during the development and clinical use of vaccines in the United States.
2. Describe one specific example where the routine clinical use of a vaccine may differ from FDA-approved product prescribing information due to the following:

(a) costs, (b) disease epidemiology, (c) public acceptance, (d) vaccine supplies.

Release and Expiration Dates

Released:  December 15, 2023
Expires:  December 15, 2026

Course Fee

$17 Pharmacist

ACPE UAN

0009-0000-23-042-H06-P

Session Code

23RW42-KXV39

Accreditation Hours

1.0 hours of CE

Additional Information

 

How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-042-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

Jeffery Aeschlimann, PharmD
Associate Clinical Professor-Infectious Disease Specialty
University of Connecticut School of Pharmacy
Storrs, CT  

Faculty Disclosure

In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

  • Dr. Aeschlimann consults with F2G, Inc. but there is no crossover in the topics, so all issues have been mitigated.

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Handouts

Post Test

 

    Immunizations (Aeschlimann) – Post-Test Questions

     

     

    1. If asked, which of the following activities would the Food and Drug Administration decline to do and send to another agency?

     

    1. Verify appropriate vaccine manufacturing processes
    2. Approve advertising for vaccine products Reporting System (VAERS)
    3. Determine the strategy for public use of vaccines in the U.S.

     

     

    2.) Which of the following items would you expect to always/very-commonly see in the FDA-Approved product labeling for a vaccine product?

     

    1. Instructions for preparation of the product and route of administration
    2. Comparative effectiveness data for people taking chronic steroid therapy
    3. Recommendations for use of lower doses in case of product shortages

     

     

    3.) Which of the following is a correct example of a vaccination situation for which ACIP has issued “Shared Clinical Decision-making” (SCDM) guidance?

     

    1. Intranasal influenza vaccine administration in immunocompromised persons
    2. Respiratory syncytial virus vaccination for adults aged 60 years and older
    3. Human papillomavirus vaccination for persons aged 16-21 years

     

     

    4.) Which entity ultimately approves the content for FDA vaccine product labeling?

     

    1. The Vaccines and Related Biological Products Advisory Committee
    2. The Center for Biologic Evaluation & Research
    3. The Center for Drug Evaluation and Research

     

     

    5.) Which of the following people would be allowed to sit in the CDC’s Advisory Committee on Immunization Practices (ACIP)?

     

    1. A member of a vaccine manufacturer’s current Board of Directors
    2. A college professor whose expertise is mechanical engineering
    3. A practicing physician who is an expert in virology and vaccine safety

     

     

    6.) What does ACIP recommend after healthcare providers receive a full series of hepatitis B immunizations?

     

    1. Serologic testing for all healthcare providers at high risk for occupational percutaneous or mucosal exposure to blood or body fluids.
    2. Serologic testing for immunocomproised healthcare providers at high risk for occupational percutaneous of any type.
    3. Molecular testing for all healthcare providers at high risk for occupational percutaneous or mucosal exposure to blood or body fluids.

    VIDEO

    Indication Deviation in Women’s Health: Off-Label Drug Use from Conception to Menopause-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    Recognize diverse instances of off-label drug use in women's health, spanning preconception to menopause
    Discuss risks and advantages associated with off-label drug utilization during

    various reproductive stages

    Identify the pharmacist's role in advocating for safe and informed off-label drug use for women’s health

    Release and Expiration Dates

    Released:  December 15, 2023
    Expires:  December 15, 2026

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-23-040-H01-P

    Session Code

    23RW40-JXT85

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-23-040-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Kelsey Giara, PharmD
    Freelance Medical Writer
    Pelham, NH

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Kelsey Giara has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    Pharmacist Post-test

    Learning Objectives
    After completing this continuing education activity, pharmacists will be able to
    • RECOGNIZE diverse instances of off-label drug use in women's health, spanning pre-conception to menopause
    • DISCUSS risks and advantages associated with off-label drug utilization during various reproductive stages
    • IDENTIFY the pharmacist's role in advocating for safe and informed off-label drug use for women’s health

    1. Which of the following can be treated through off-label use of metformin?
    A. Hirsutism of PCOS
    B. PCOS with BMI ≥ 25 kg/m2
    C. Endometriosis

    2. Which of the following medications is used off-label to induce ovulation in women experiencing infertility and trying to conceive?
    A. Letrozole
    B. Clomiphene citrate
    C. Cetrorelix

    3. Which of the following drugs is used off-label to treat menopausal hot flashes?
    A. Clonidine
    B. Paroxetine
    C. Fezolinetant

    4. Which of the following is TRUE about off-label medication use during pregnancy?
    A. All drugs have sufficient efficacy and safety data to support their use during pregnancy
    B. Providers should use the letter-based FDA rating system to aid in shared clinical decision-making
    C. About three-quarters of pregnant women use medications for off-label uses during pregnancy

    5. A patient comes to your pharmacy experiencing frequent hot flashes. She states that a friend suggested she try taking black cohosh. She takes lisinopril for hypertension and metformin for prediabetes, and she is otherwise healthy. Which of the following is the BEST response?
    A. Black cohosh will interact with your blood pressure medication, so you should not take it. Ask your doctor about clonidine instead.
    B. Black cohosh shows some benefit, but clinical trials are inconsistent and available data is insufficient. You can try taking 20 mg daily for a few weeks to see if your symptoms improve.
    C. Black cohosh shows no benefit whatsoever for VMS of menopause. Ask your doctor about letrozole instead.

    6. Which of the following is TRUE about Pregnancy Exposure Registries?
    A. They steal data about women’s babies and sell it on the black market
    B. They are FDA-sponsored registries that collect health information
    C. Pregnant women volunteer to share their experiences with off-label drug use

    Handouts

    VIDEO

    PATIENT SAFETY: Biosimilar Doppelgangers-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    • Compare and contrast a small molecule drug from a biological drug
    • Compare and contrast how a reference biologic drug compares with its biosimilar
    • Describe where a pharmacist would identify a biosimilar product and the legal implications of a biosimilar achieving interchangeable status with a reference product
    • Describe the nocebo effect and how to prevent it from occurring
    • Apply the knowledge from the objectives above to specific patient care scenarios in the self-assessment questions

    Release and Expiration Dates

    Released:  December 19, 2025
    Expires:  December 19, 2025

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-26-066-H05-P

    Session Code

    25RW66-DGB13

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-066-H05-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    C. Michael White, PharmD, FCCP, FCP
    BOT Distinguished Professor and Chair of Pharmacy Practice
    University of Connecticut School of Pharmacy
    Storrs, CT              

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. White has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Posttest

    Patient Safety: Biosimilar Doppelgangers
    25-066 Posttest

    1. When a rituximab-arrx biosimilar is prescribed, how can you preempt the patient from falling victim to the nocebo effect?
    a) Reinforce that biosimilars are inexpensive but equally effective and safe versions of the biologic they were taking
    b) Go into the deep science and talk about tertiary protein folding difference but that they are not in the critical molecular areas
    c) Tell them about how the deep state is out to get them and that taking a biosimilar leads to brainwashing impelled prescribing of 5G linked vaccines that makes people “Libtards”

    *

    2. You made the substitution to rituximab-arrx and three years go by with no issues. Then the efficacy starts to wane, and some flair ups occurs. What is the best course of action for the patient?
    a) Switch back to the reference biologic rituximab
    b) Switch to another biosimilar rituximab-pvvr
    c) Switch to a biologic drug in another class

    *

    3. A patient has been successfully taking adalimumab-ryvk for a year now but, due to a supply chain issue, you do not have it in stock. Can you automatically substitute it for adalimumab-adbm?
    a) You would look at the Purple Book and if one of them is an interchangeable biosimilar, the answer is yes
    b) You can always automatically substitute a biosimilar to another biosimilar regardless if one is interchangeable or not
    c) You are not allowed to automatically swap out one biosimilar for another even if they are both interchangeable with a reference (you need to call the prescriber and get a new prescription)

    *

    4. How is a biosimilar different from a generic drug?
    a) A biosimilar is a small molecule product while generic drugs are large molecule
    b) A biosimilar requires both immunogenicity assessments and pharmacodynamic assessments while generic drugs do not
    c) A generic drug requires both immunogenicity assessments and pharmacodynamic assessments while biosimilars do not

    *

    5. Which of the following would not promote defining something as a biologic?
    a) Expensive price
    b) Monoclonal antibody
    c) Made from living cells

    *

    6. Which of the following is true of an interchangeable biologic product vs. a biosimilar?
    a) In all states, pharmacists can automatically substitute an interchangeable biologic product for an innovator product but would need a new prescription to dispense a biosimilar without interchangeable status.
    b) Interchangeable biologic products are likely to have the same efficacy and safety as biosimilar products without interchangeable status.
    c) The FDA is considering making interchangeable status harder to obtain by strengthening the evidence standards.

    Handouts

    VIDEO

    IIMMUNIZATION: Mountebanks, Grifters, and Frauds (Oh My!): An Update on the Management of Vaccine-Preventable Illnesses in 2025-RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

     

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    • Describe at least one important change (or proposed change) in childhood and adult vaccination recommendations put forth by the CDC and/or ACIP
    • Given a patient who inquires about receiving respiratory virus or bacteria vaccinations (e.g., Influenza, COVID-19, Respiratory Syncytial Virus (RSV), Pneumococcal), outline important differences between multiple products when they exist
    • Identify evidence-based pharmacotherapeutic treatments for common vaccine-preventable illnesses

    Release and Expiration Dates

    Released:  December 19, 2025
    Expires:  December 19, 2028

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-25-069-H06-P

    Session Code

    25RW69-MGF85

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-069-H06-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Jeffery Aeschlimann, PharmD
    Associate Clinical Professor-Infectious Disease Specialty
    University of Connecticut School of Pharmacy
    Storrs, CT  

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Aeschlimann consults with F2G, Inc. but there is no crossover in the topics, so all issues have been mitigated.

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    1. Which of the following recommendations did ACIP approve in 2025?
      1. All adults receive single dose thimerosal-free seasonal influenza vaccine formulations free
      2. State and local jurisdictions should require a prescription for the administration of a COVID-19 vaccination
      3. COVID-19 vaccination should be administered to all adults 55 and older
    2. Baby Boy Blue develops measles today; the rash is widespread on his body and he cries incessantly. He has three unvaccinated siblings. His mom asks what the contagious period is and how contagious the infection is. What is the CORRECT answer?
      1. Measles are contagious for roughly five days after the rash’s appearance, and they are not terribly contagious.
      2. Measles are contagious for plus or minus five days of the rash’s appearance, and they are highly contagious.
      3. Measles are contagious only in the week before the rash’s appearance, and they are highly contagious.
    3. Mom is surprised and braces herself for all of her children to contract measles; she heard that taking an antiviral will help. She asks if there is a pill that will help. What do you say?
      1. The FDA has not approved any antiviral therapies to treat measles.
      2. The most appropriate antiviral is daily vitamin A for at least 14 days.
      3. She should ask her pediatrician for a prescription for acyclovir.
    4. Mom is very concerned. She asks if there is anything she can do to protect her other children. Is there?
      1. No, she needs to ride out the storm and rethink her stance on vaccinations.
      2. Yes, she should ask a family member to host her children until Baby Boy Blue is better.
      3. Yes, her children can get post-exposure prophylaxis with MMR vaccine within 72 hours
    5. The ACIP panel voted to remove the option to use the MMRV vaccine in children younger than 47 months old. Why?
      1. ACIP cited slightly higher risks of tonic-clonic seizures for MMRV vs. separately administered doses of MMR & VARIVAX
      2. ACIP cited slightly higher risks of petit mal seizures for MMRV vs. separately administered doses of MMR & VARIVAX
      3. ACIP cited a slightly higher risks of fevers/febrile seizures for MMRV vs. separately administered doses of MMR & VARIVAX
    6. Two children of 2700 in a premarketing study experienced seizures after receiving the MMRV vaccine. What other characteristic did they share?
      1. They appeared to have a concurrent viral illness during vaccination.
      2. They appeared to have a vitamin A deficit of longstanding duration.
      3. They appeared to have contracted a cold shortly after vaccination.
    7. How many doses of hepatitis B vaccine are necessary to achieve protection at the 95% level?
      1. One
      2. Two
      3. Three
    8. A 70-year-old male comes to the consultation window of your pharmacy. He would like to receive a vaccination for the flu. His only chronic health issues are hypertension and hypercholesterolemia (both effectively managed). You have three vaccines in stock. Which of the following products would be PREFERRED to administer to this patient?
      1. Inactivated influenza vaccine (IIV3, Afluria)
      2. High-dose inactivated influenza vaccine (HD-IIV3, Fluzone High-Dose)
      3. Adjuvanted inactivated influenza vaccine (aIIV3, Fluad)

    VIDEO

    NKOTB: New and Emerging Roles for GLP-1-Based Medications -RECORDED WEBINAR

    About this Course

    This course is a recorded (home study version) of the 2025 CE Finale Encore Webinars.

     

    * The information below is current as of the time of the presentation in 12/2025. This is a very active and rapidly-changing area of research so the information may have changed by the time the audience member watches this presentation in the future.

    Learning Objectives

    Upon completion of this application based CE Activity, a pharmacist will be able to:

    • List recent FDA-approved indications for GLP-1-based medications
    • Recognize proposed mechanisms by which GLP-1-based medications may impact conditions beyond type 2 diabetes and adiposity-based chronic disease
    • Describe key findings from major clinical trials evaluating new therapeutic potential of GLP-1-based medications

    Release and Expiration Dates

    Released:  December 19, 2025
    Expires:  December 19, 2028

    Course Fee

    $17 Pharmacist

    ACPE UAN

    0009-0000-25-065-H01-P

    Session Code

    25RW65-GLP35

    Accreditation Hours

    1.0 hours of CE

    Additional Information

     

    How to Complete Evaluation:  When you are ready to submit quiz answers, go to the BLUE take test/evaluation button.

    Accreditation Statement

    The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

    Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive up to 1.0 CE Hours (or 0.1 CEUs)  for completing the activity ACPE UAN 0009-0000-25-065-H01-P, passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

    Grant Funding

    There is no grant funding for this activity.

    Faculty

    Khanh Dang, PharmD, CDCES, FNAP
    Clinical Professor
    UConn School of Pharmacy
    Storrs, CT

    Faculty Disclosure

    In accordance with the Accreditation Council for Pharmacy Education (ACPE) Criteria for Quality and Interpretive Guidelines, The University of Connecticut School of Pharmacy requires that faculty disclose any relationship that the faculty may have with commercial entities whose products or services may be mentioned in the activity.

    • Dr. Dang has no relationships with ineligible companies

    Disclaimer

    The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

    Content

    Post Test

    1. Which of the following GLP-1-based medication has an FDA indication for reducing risk sustained eGFR decline, end-stage kidney disease and CV death in adults with type 2 diabetes mellitus and CKD?
    A. dulaglutide
    B. semaglutide
    C. tirzepatide

    *

    2. Which of the following GLP-1-based medication has an FDA indication for obstructive sleep apnea (OSA)?
    A. dulaglutide
    B. semaglutide
    C. tirzepatide

    *

    3. Which of the following mechanisms contributes to the cardiovascular risk reduction observed with GLP-1-based medications?
    A. Direct blockade of angiotensin II receptors and weight loss
    B. Improved endothelial function, decreased blood pressure, and weight loss
    C. Increasing sympathetic nervous system activity

    *

    4. In the FLOW study, which supported semaglutide’s recent FDA label approval for kidney risk reduction, the primary composite endpoint (kidney failure, ≥50% sustained eGFR reduction, or kidney/cardiovascular death) was reduced by ____ compared to placebo.
    A. ~10%
    B. ~25%
    C. ~50%

    *

    5. Which patient population was enrolled in the SURMOUNT-OSA study?
    A. Adults with obstructive sleep apnea and normal body weight
    B. Adults with BMI of 30 and higher and obstructive sleep apnea, with or without positive airway pressure therapy
    C. Adults with central sleep apnea due to neurologic disease, receiving with positive airway pressure therapy

    *

    6. Which of the following is a proposed mechanism of how GLP-1-based medications can lead to both renal protection and improvement in metabolic-dysfunction steatohepatitis (MASH)?
    A. Decreased inflammation
    B. Increased insulin resistance
    C. Increased blood pressure

    Video